NASDAQ:VCEL - Vericel Stock Price, Price Target & More

$11.80 -0.20 (-1.67 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$11.80
Today's Range$11.60 - $12.1750
52-Week Range$2.35 - $13.20
Volume610,920 shs
Average Volume940,579 shs
Market Capitalization$437.27 million
P/E Ratio-23.60
Dividend YieldN/A
Beta3.18

About Vericel (NASDAQ:VCEL)

Vericel logoVericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCEL
CUSIPN/A
Phone800-556-0311

Debt

Debt-to-Equity Ratio0.75%
Current Ratio3.86%
Quick Ratio3.57%

Price-To-Earnings

Trailing P/E Ratio-23.60
Forward P/E Ratio-34.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$63.92 million
Price / Sales6.73
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book18.15

Profitability

EPS (Most Recent Fiscal Year)($0.50)
Net Income$-17,280,000.00
Net Margins-27.04%
Return on Equity-98.77%
Return on Assets-39.49%

Miscellaneous

Employees205
Outstanding Shares36,440,000

How to Become a New Pot Stock Millionaire

Vericel (NASDAQ:VCEL) Frequently Asked Questions

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

How were Vericel's earnings last quarter?

Vericel (NASDAQ:VCEL) issued its earnings results on Monday, March, 5th. The biotechnology company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.13. The biotechnology company had revenue of $23.35 million for the quarter. Vericel had a negative return on equity of 98.77% and a negative net margin of 27.04%. View Vericel's Earnings History.

When is Vericel's next earnings date?

Vericel is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Vericel.

What price target have analysts set for VCEL?

5 brokers have issued 12 month price objectives for Vericel's shares. Their predictions range from $13.00 to $15.00. On average, they anticipate Vericel's stock price to reach $14.25 in the next year. View Analyst Ratings for Vericel.

Who are some of Vericel's key competitors?

Who are Vericel's key executives?

Vericel's management team includes the folowing people:
  • Mr. Dominick C. Colangelo Esq., Chief Exec. Officer, Pres, Treasurer and Director (Age 54)
  • Mr. Gerard J. Michel MS, MBA, Chief Financial Officer and VP of Corp. Devel. (Age 55)
  • Mr. Daniel R. Orlando, Chief Operating Officer (Age 53)
  • Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel and Corp. Sec.
  • Ms. Heidi Hassen, Sr. Director of HR

Has Vericel been receiving favorable news coverage?

Press coverage about VCEL stock has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vericel earned a news impact score of 0.11 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.09 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $11.80.

How big of a company is Vericel?

Vericel has a market capitalization of $437.27 million and generates $63.92 million in revenue each year. The biotechnology company earns $-17,280,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vericel employs 205 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]


MarketBeat Community Rating for Vericel (VCEL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vericel (NASDAQ:VCEL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Vericel in the last 12 months. Their average twelve-month price target is $14.25, suggesting that the stock has a possible upside of 20.76%. The high price target for VCEL is $15.00 and the low price target for VCEL is $13.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.753.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.25$14.00$7.6667$6.3333
Price Target Upside: 20.76% upside18.14% upside29.94% upside5.56% upside

Vericel (NASDAQ:VCEL) Consensus Price Target History

Price Target History for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ:VCEL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018Leerink SwannInitiated CoverageOutperform -> Outperform$15.00HighView Rating Details
3/6/2018Needham & Company LLCBoost Price TargetBuy -> Buy$5.00 -> $15.00HighView Rating Details
3/6/2018Ladenburg ThalmannDowngradeBuy -> NeutralHighView Rating Details
3/5/2018BTIG ResearchReiterated RatingBuy -> Buy$8.00 -> $13.00HighView Rating Details
3/5/2018Piper JaffrayBoost Price TargetOverweight$14.00HighView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Vericel (NASDAQ:VCEL) Earnings History and Estimates Chart

Earnings by Quarter for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ:VCEL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.31)
2019 EPS Consensus Estimate: ($0.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.06)($0.06)($0.06)
Q3 20181($0.11)($0.11)($0.11)
Q4 20181$0.02$0.02$0.02
Q1 20191($0.11)($0.11)($0.11)
Q2 20191$0.01$0.01$0.01
Q3 20191($0.05)($0.05)($0.05)
Q4 20191$0.10$0.10$0.10

Vericel (NASDAQ VCEL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
3/5/2018Q4 2017($0.10)$0.03$23.35 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.17)($0.16)$14.26 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.24)($0.08)$16.95 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.19)($0.31)$9.36 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.22)($0.14)$16.52 millionViewN/AView Earnings Details
11/7/2016Q3($0.28)($0.38)$10.93 millionViewListenView Earnings Details
8/8/2016Q2 2016($0.21)$12.82 millionViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.08)$11.60 million$14.10 millionViewListenView Earnings Details
3/14/2016Q415($0.15)($0.28)$17.36 million$15.40 millionViewListenView Earnings Details
11/13/2015Q315($0.21)($0.26)$10.50 million$11.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.16)$11.31 million$13.60 millionViewListenView Earnings Details
5/14/2015Q115($0.14)($0.27)$11.10 million$10.80 millionViewListenView Earnings Details
3/23/2015Q414($0.47)($0.17)$10.70 million$14.70 millionViewListenView Earnings Details
11/13/2014Q314($0.66)($0.52)$6.73 million$9.66 millionViewN/AView Earnings Details
8/14/2014Q214($1.59)($0.94)$2.50 million$4.43 millionViewN/AView Earnings Details
5/15/2014Q114($0.92)($1.26)ViewN/AView Earnings Details
3/13/2014Q413($1.34)($0.97)$0.0190 million$0.0080 millionViewN/AView Earnings Details
11/12/2013Q3($2.02)($0.06)ViewListenView Earnings Details
8/7/2013Q2 2013($2.40)($2.20)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.19)($0.15)$0.01 millionViewN/AView Earnings Details
3/18/2013Q4 2012($4.60)($4.00)ViewN/AView Earnings Details
11/8/2012Q3 2012($4.80)($4.40)ViewN/AView Earnings Details
8/7/2012Q2 2012($4.60)($5.40)ViewN/AView Earnings Details
5/10/2012Q1 2012($4.00)($4.56)ViewN/AView Earnings Details
3/12/2012Q4 2011($3.80)($4.06)ViewN/AView Earnings Details
11/8/2011Q3 2011($3.60)($1.00)ViewN/AView Earnings Details
8/15/2011Q2 2011($3.40)($3.88)ViewN/AView Earnings Details
5/16/2011Q1 2011($3.80)($2.58)ViewN/AView Earnings Details
2/28/2011Q4 2010($3.40)($8.86)ViewN/AView Earnings Details
11/8/2010Q3 2010($3.60)($4.12)ViewN/AView Earnings Details
8/17/2010Q2 2010($2.80)($3.62)ViewN/AView Earnings Details
5/10/2010Q1 2010($3.18)ViewN/AView Earnings Details
2/10/2010Q4 2009($4.16)ViewN/AView Earnings Details
11/6/2009Q3 2009($3.68)ViewN/AView Earnings Details
9/14/2009Q2 2009($4.80)ViewN/AView Earnings Details
5/8/2009Q1 2009($4.32)ViewN/AView Earnings Details
2/6/2009Q4 2008($4.80)ViewN/AView Earnings Details
11/7/2008Q3 2008($4.64)ViewN/AView Earnings Details
8/29/2008Q2 2008($6.40)($5.92)ViewN/AView Earnings Details
5/12/2008Q1 2008($6.40)($6.08)ViewN/AView Earnings Details
2/8/2008Q4 2007($6.40)($6.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vericel (NASDAQ:VCEL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vericel (NASDAQ VCEL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 36.91%
Insider Trading History for Vericel (NASDAQ:VCEL)
Insider Trading History for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ VCEL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2018Alan L RubinoDirectorBuy890$11.57$10,297.30165View SEC Filing  
3/28/2016Consonance Capital ManagementMajor ShareholderSell120,000$5.39$646,800.00View SEC Filing  
9/16/2014Daniel OrlandoCOOBuy9,804$2.55$25,000.20View SEC Filing  
9/16/2014Dominick ColangeloCEOBuy20,000$2.55$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vericel (NASDAQ VCEL) News Headlines

Source:
DateHeadline
$16.51 Million in Sales Expected for Vericel (VCEL) This Quarter$16.51 Million in Sales Expected for Vericel (VCEL) This Quarter
www.americanbankingnews.com - April 19 at 2:28 AM
Zacks: Brokerages Expect Vericel (VCEL) to Announce -$0.15 Earnings Per ShareZacks: Brokerages Expect Vericel (VCEL) to Announce -$0.15 Earnings Per Share
www.americanbankingnews.com - April 17 at 7:08 PM
Q1 2018 EPS Estimates for Vericel (VCEL) Cut by Leerink SwannQ1 2018 EPS Estimates for Vericel (VCEL) Cut by Leerink Swann
www.americanbankingnews.com - April 16 at 1:14 AM
Vericel to Post Q2 2019 Earnings of $0.01 Per Share, Leerink Swann Forecasts (VCEL)Vericel to Post Q2 2019 Earnings of $0.01 Per Share, Leerink Swann Forecasts (VCEL)
www.americanbankingnews.com - April 13 at 9:41 AM
Vericel (VCEL) Upgraded to Strong-Buy at BidaskClubVericel (VCEL) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - April 13 at 9:39 AM
Vericel Stock Looks to Break Out From Prior HighsVericel Stock Looks to Break Out From Prior Highs
finance.yahoo.com - April 13 at 9:33 AM
Harry Boxer’s five biotech stocks to watchHarry Boxer’s five biotech stocks to watch
finance.yahoo.com - April 11 at 4:39 PM
Will Vericel (VCEL) Continue to Surge Higher? April 11, 2018Will Vericel (VCEL) Continue to Surge Higher? April 11, 2018
www.zacks.com - April 11 at 9:51 AM
Will Vericel (VCEL) Continue to Surge Higher?Will Vericel (VCEL) Continue to Surge Higher?
finance.yahoo.com - April 11 at 9:51 AM
Vericel (VCEL) PT Set at $6.00 by BTIG ResearchVericel (VCEL) PT Set at $6.00 by BTIG Research
www.americanbankingnews.com - April 11 at 12:43 AM
Piper Jaffray Reaffirms "Buy" Rating for Vericel (VCEL)Piper Jaffray Reaffirms "Buy" Rating for Vericel (VCEL)
www.americanbankingnews.com - April 10 at 10:31 PM
Vericel to Present at the 6th Annual Cell & Gene Therapy Investor DayVericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
finance.yahoo.com - April 10 at 9:38 AM
Leerink Swann Weighs in on Vericels Q1 2018 Earnings (VCEL)Leerink Swann Weighs in on Vericel's Q1 2018 Earnings (VCEL)
www.americanbankingnews.com - April 6 at 8:30 AM
Vericel: Breakthrough Cell Therapy Fueling Rapid GrowthVericel: Breakthrough Cell Therapy Fueling Rapid Growth
seekingalpha.com - April 5 at 4:36 PM
Today’s Research Reports on Trending Tickers: Vericel Corporation and RXi PharmaceuticalsToday’s Research Reports on Trending Tickers: Vericel Corporation and RXi Pharmaceuticals
finance.yahoo.com - April 5 at 9:18 AM
Vericel (VCEL) Now Covered by Leerink SwannVericel (VCEL) Now Covered by Leerink Swann
www.americanbankingnews.com - April 4 at 9:30 AM
Vericel (VCEL) Upgraded by ValuEngine to BuyVericel (VCEL) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - April 2 at 10:52 PM
3 Biotech Stocks Hitting New Highs3 Biotech Stocks Hitting New Highs
finance.yahoo.com - April 2 at 9:43 AM
Vericel (VCEL) Receives Consensus Rating of "Buy" from BrokeragesVericel (VCEL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 1 at 5:48 AM
 Analysts Anticipate Vericel (VCEL) to Post -$0.13 EPS Analysts Anticipate Vericel (VCEL) to Post -$0.13 EPS
www.americanbankingnews.com - March 31 at 7:14 PM
Vericel (VCEL) Rating Reiterated by Piper JaffrayVericel (VCEL) Rating Reiterated by Piper Jaffray
www.americanbankingnews.com - March 31 at 10:56 AM
Vericel (VCEL) Given a $8.00 Price Target at BTIG ResearchVericel (VCEL) Given a $8.00 Price Target at BTIG Research
www.americanbankingnews.com - March 31 at 12:46 AM
Vericel (VCEL) Cut to Buy at BidaskClubVericel (VCEL) Cut to Buy at BidaskClub
www.americanbankingnews.com - March 30 at 11:07 AM
Vericel (VCEL) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowVericel (VCEL) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:38 PM
Vericel (VCEL) Presents At BioCenturys 25th Annual Future Leaders In The Biotech Industry Conference - SlideshowVericel (VCEL) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow
seekingalpha.com - March 29 at 9:36 AM
Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical ...Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical ...
globenewswire.com - March 24 at 4:34 PM
Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five YearsVericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
finance.yahoo.com - March 23 at 9:14 AM
Alan L. Rubino Purchases 890 Shares of Vericel Corp (VCEL) StockAlan L. Rubino Purchases 890 Shares of Vericel Corp (VCEL) Stock
www.americanbankingnews.com - March 20 at 1:24 PM
Vericel to Present at the 17th Annual Needham Healthcare Conference - GlobeNewswire (press release)Vericel to Present at the 17th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 13 at 6:30 PM
Vericel to Present at the 17th Annual Needham Healthcare ConferenceVericel to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 13 at 6:30 PM
Vericel to Host Analyst and Investor Day on April 11, 2018Vericel to Host Analyst and Investor Day on April 11, 2018
finance.yahoo.com - March 12 at 5:42 PM
Vericel (VCEL) Lifted to "Strong-Buy" at BidaskClubVericel (VCEL) Lifted to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 11 at 2:23 PM
Vericel to Present at BioCenturys 25th Annual Future Leaders in the Biotech Industry Conference - GlobeNewswire (press release)Vericel to Present at BioCentury's 25th Annual Future Leaders in the Biotech Industry Conference - GlobeNewswire (press release)
globenewswire.com - March 9 at 9:43 AM
Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry ConferenceVericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
finance.yahoo.com - March 9 at 9:43 AM
Ladenburg Thalmann Downgrades Vericel Corporation (VCEL) to Neutral; Valuation FullLadenburg Thalmann Downgrades Vericel Corporation (VCEL) to Neutral; Valuation Full
www.streetinsider.com - March 8 at 9:34 AM
Stock Traders Purchase Large Volume of Vericel Call Options (VCEL)Stock Traders Purchase Large Volume of Vericel Call Options (VCEL)
www.americanbankingnews.com - March 7 at 7:26 AM
Vericel Corp (VCEL) Receives Average Recommendation of "Buy" from AnalystsVericel Corp (VCEL) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 7 at 5:58 AM
Vericel (VCEL) Downgraded by Ladenburg Thalmann Financial Services to NeutralVericel (VCEL) Downgraded by Ladenburg Thalmann Financial Services to Neutral
www.americanbankingnews.com - March 7 at 12:00 AM
Today’s Research Reports on Trending Tickers: GlycoMimetics, Inc. and Vericel CorporationToday’s Research Reports on Trending Tickers: GlycoMimetics, Inc. and Vericel Corporation
finance.yahoo.com - March 6 at 9:07 AM
Vericel (VCEL) Price Target Raised to $15.00Vericel (VCEL) Price Target Raised to $15.00
www.americanbankingnews.com - March 6 at 8:42 AM
Vericel (VCEL) Issues  Earnings Results, Beats Expectations By $0.08 EPSVericel (VCEL) Issues Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - March 5 at 8:38 PM
World Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with Vericel for the ‘It’s Your Move’ CampaignWorld Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with Vericel for the ‘It’s Your Move’ Campaign
finance.yahoo.com - March 5 at 5:10 PM
Vericel Corp (VCEL) Shares Are Skyrocketing On Record 4Q RevenuesVericel Corp (VCEL) Shares Are Skyrocketing On Record 4Q Revenues
finance.yahoo.com - March 5 at 5:10 PM
Why Vericel Jumped Higher TodayWhy Vericel Jumped Higher Today
finance.yahoo.com - March 5 at 5:10 PM
XL Group, Treehouse Foods rise; Blue Apron, Dermira fallXL Group, Treehouse Foods rise; Blue Apron, Dermira fall
marketbeat.com - March 5 at 4:54 PM
Vericel (VCEL) Stock Rating Reaffirmed by BTIG ResearchVericel (VCEL) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - March 5 at 4:00 PM
Vericel (VCEL) Price Target Increased to $14.00 by Analysts at Piper Jaffray CompaniesVericel (VCEL) Price Target Increased to $14.00 by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - March 5 at 1:36 PM
6 Stocks To Watch For March 5, 2018 - Benzinga6 Stocks To Watch For March 5, 2018 - Benzinga
www.benzinga.com - March 5 at 9:24 AM
Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance - GlobeNewswire (press release)Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance - GlobeNewswire (press release)
globenewswire.com - March 5 at 9:24 AM
Pre-Market Earnings Report for March 5, 2018 : VCEL, ARQL - NasdaqPre-Market Earnings Report for March 5, 2018 : VCEL, ARQL - Nasdaq
www.nasdaq.com - March 3 at 5:23 PM

SEC Filings

Vericel (NASDAQ:VCEL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vericel (NASDAQ:VCEL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vericel (NASDAQ VCEL) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.